Smit, Kyra N.
Boers, Ruben
Vaarwater, Jolanda
Boers, Joachim
Brands, Tom
Mensink, Hanneke
Verdijk, Robert M.
van IJcken, Wilfred F. J.
Gribnau, Joost
de Klein, Annelies
Kilic, Emine
Funding for this research was provided by:
Stichting Combined Ophthalmic Research Rotterdam (4.2.0)
Article History
Received: 13 September 2021
Accepted: 1 December 2021
First Online: 7 January 2022
Competing interests
: The authors declare no conflict of interest of financial interests except for R.B, J.B., W.V.I. and J.G. who report being shareholder in Methylomics B.V., a commercial company that applies MeD-seq to develop methylation markers for cancer staging.